Orlistat: current status in clinical therapeutics (Q37649644)

21 August 2017

1 reference

title

Orlistat: current status in clinical therapeutics (English)

1 reference

21 August 2017

Katie S McClendon

1

1 reference

21 August 2017

Daniel M Riche

series ordinal

2

1 reference

21 August 2017

Gabriel Ikponmosa Uwaifo

series ordinal

3

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

Expert Opinion on Drug Safety

21 August 2017

published in

1 reference

21 August 2017

volume

8

1 reference

21 August 2017

issue

6

1 reference

21 August 2017

page(s)

727-744

1 reference

Syntheses of Tetrahydrolipstatin and Absolute Configuration of Tetrahydrolipstatin and Lipstatin

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Orlistat in the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Obesity, gut hormones, and bariatric surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Pharmacological treatment of the overweight patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Effect of acarbose on insulin sensitivity in elderly patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

The alpha-glucosidase inhibitor acarbose prevents obesity and simple steatosis in sequestosome 1/A170/p62 deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Prevention of Type 2 diabetes: fact or fiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Overweight and obesity: key components of cardiometabolic risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Orlistat in the prevention of diabetes in the obese patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Orlistat increases serum paraoxonase activity in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Short-term administration of orlistat reduced daytime triglyceridemia in obese women with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

The role of colesevelam HCl in type 2 diabetes mellitus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

The use of colesevelam HCl in patients with type 2 diabetes mellitus: combining glucose- and lipid-lowering effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

The effect of orlistat-induced weight loss on interleukin-6 and C-reactive protein levels in obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Lipid peroxides in obese patients and effects of weight loss with orlistat on lipid peroxides levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Effect of orlistat on postprandial lipemia, NMR lipoprotein subclass profiles and particle size

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Orlistat for obesity: benefits beyond weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

A gastrointestinal lipase inhibitor reduces progression of atherosclerosis in mice fed a western-type diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Orlistat: a review of its use in the management of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Effects of Orlistat, a Lipase Inhibitor, on the Pharmacokinetics of Three Highly Lipophilic Drugs (Amiodarone, Fluoxetine, and Simvastatin) in Healthy Volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

The Effect of Short-Term (21-Day) Orlistat Treatment on the Physiologic Balance of Six Selected Macrominerals and Microminerals in Obese Adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Orlistat: selective inhibition of caloric absorption can affect long-term body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Pharmacological therapy of obesity: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Effect of orlistat in obese patients with binge eating disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Effects of orlistat on fat-soluble vitamins in obese adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Effect of orlistat in overweight poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Does metabolic syndrome mitigate weight loss in overweight Mexican American women treated for 1-year with orlistat and lifestyle modification?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Improvement in hypertrophic cardiomyopathy after significant weight loss: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Addition of orlistat to conventional treatment in adolescents with severe obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Meta-analysis: pharmacologic treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

A systematic review of the clinical effectiveness of orlistat used for the management of obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Screening and interventions for obesity in adults: summary of the evidence for the U.S. Preventive Services Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Long term pharmacotherapy for obesity and overweight: updated meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Orlistat and sibutramine beyond weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Clinical review: treatment of pediatric obesity: a systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Over-the-counter orlistat. A weight loss "Alli" or adversary on the horizon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Compliance, behavior change, and weight loss with orlistat in an over-the-counter setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

An RCT of metformin versus orlistat for the management of obese anovulatory women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Short-term effect of orlistat on dietary glycotoxins in healthy women and women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Orlistat treatment of unconjugated hyperbilirubinemia in Crigler-Najjar disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Influence of dietary composition on the inhibition of fat absorption by orlistat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Safety profile of orlistat: results of a prescription-event monitoring study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Orlistat enhances warfarin effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Orlistat-associated adverse effects and drug interactions: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Hypothyroidism in thyroid carcinoma follow-up: orlistat may inhibit the absorption of thyroxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Drug interaction in a renal transplant patient: cyclosporin-Neoral and orlistat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Reduction in blood cyclosporine concentration by orlistat in two renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Influence of topiramate on olanzapine-related weight gain in women: an 18-month follow-up observation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Epidemiology of obesity in the Western Hemisphere

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Recent trends in waist circumference and waist-height ratio among US children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Obesity, metabolic syndrome, and type 2 diabetes: emerging epidemics and their cardiovascular implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Trends in obesity and abdominal obesity among hypertensive and nonhypertensive adults in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Trends in risk factors for cardiovascular disease among children and adolescents in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Increasing prevalence of the metabolic syndrome among u.s. Adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Trends in waist circumference among U.S. adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Comparison of efficacy of sibutramine or orlistat versus their combination in obese women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Impact of orlistat therapy on weight reduction in morbidly obese patients after implantation of the Swedish adjustable gastric band

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Orlistat for the long-term treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Implications of a new definition of vitamin D deficiency in a multiracial us adolescent population: the National Health and Nutrition Examination Survey III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Vitamin D in overweight/obese women and its relationship with dietetic and anthropometric variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Is there a link between calcium oxalate crystalluria, orlistat and acute tubular necrosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

A possibly overlooked side effect of Orlistat: gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Additive gastrointestinal effects with concomitant use of olestra and orlistat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Bulimia nervosa and misuse of orlistat: two case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Myopathy associated with chronic orlistat consumption: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

36 year old man presenting with pancreatitis and a history of recent commencement of Orlistat case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Massive hepatocellular [correction of hepatocullular] necrosis: was it caused by Orlistat?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Orlistat-induced cutaneous leukocytoclastic vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Diabetic ketoacidosis associated with orlistat treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740330903321485

Interventions for treating obesity in children

21 January 2018

1 reference

COCI

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD001872.PUB2

10.1517/14740330903321485

12 January 2024

Identifiers

DOI

1 reference

21 August 2017

1 reference